Pliant Therapeutics Stock Analysis

Pliant Stock Analysis Notes

About 97.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.31. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pliant Therapeutics recorded a loss per share of 3.47. The entity had not issued any dividends in recent years. Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. Pliant Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. To find out more about Pliant Therapeutics contact MBA MD at 650 481 6770 or learn more at https://pliantrx.com.

Pliant Therapeutics Investment Alerts

Pliant Therapeutics Upcoming and Recent Events

Pliant Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 94.92 M.

Technical Drivers

As of the 24th of March, Pliant Therapeutics holds the Coefficient Of Variation of (598.90), variance of 168.88, and Risk Adjusted Performance of (0.14). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pliant Therapeutics, as well as the relationship between them.

Pliant Therapeutics Price Movement Analysis

Pliant Therapeutics Insider Trading Activities

Pliant Therapeutics Outstanding Bonds

Pliant Therapeutics Predictive Daily Indicators

Pliant Therapeutics Forecast Models

Pliant Therapeutics' time-series forecasting models are one of many Pliant Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pliant Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Pliant Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Pliant shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Pliant Therapeutics. By using and applying Pliant Stock analysis, traders can create a robust methodology for identifying Pliant entry and exit points for their positions.

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.